Exhibit 10.1


 


SECURITIES PURCHASE AGREEMENT


 


SECURITIES PURCHASE AGREEMENT
(the “Agreement”),
dated as of June 24, 2003 by and among SuperGen, Inc., a Delaware corporation,
with headquarters located at 4140 Dublin Boulevard, Suite 200, Dublin,
California 94568 (the “Company”), and the investors listed on the
Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the
“Buyers”).


 


WHEREAS:


 


A.           The
Company and each Buyer is executing and delivering this Agreement in reliance
upon the exemption from securities registration afforded by Section 4(2) of the
Securities Act of 1933, as amended (the “1933 Act”), and Rule 506 of Regulation D (“Regulation D”)
as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the 1933 Act;


 


B.             The
Company has authorized senior convertible notes of the Company in the form
attached hereto as Exhibit A (together with any senior convertible notes
issued in replacement or exchange thereof in accordance with the terms thereof,
the “Notes”),
which Notes shall be, in accordance with the terms of the Notes, in whole or in
part, convertible into shares of the Company’s common stock, par value $.001
per share (“Company Common Stock”) (as converted, the “Conversion
Shares”);


 


C.             The
Notes bear interest, which at the option of the Company, subject to certain
conditions, may be paid in shares of Company Common Stock (“Interest
Shares”);


 


D.            Each
Buyer wishes to purchase, severally but not jointly, and the Company wishes to
sell, upon the terms and conditions stated in this Agreement, (i) that
aggregate principal amount of Notes set forth opposite such Buyer’s name in
column (3) on the Schedule of Buyers (which aggregate principal amount for all
Buyers shall be $21,250,000) and (ii) warrants, in substantially the form
attached hereto as Exhibit B (the “Warrants”), to acquire that number of
shares of the common stock, par value $.0001 per share (“AVII Common Stock”), of AVI BioPharma, Inc.
(“AVII”) (as exercised,
collectively, the “Warrant Shares”) set forth opposite such
Buyer’s name in column (4) on the Schedule of Buyers (with the aggregate number
of Warrant Shares for all Buyers being 2,634,211 Warrant Shares (the “AVII Shares”));


 


E.              The
Company is agreeing to pledge the AVII Shares to secure its obligations to
deliver AVII Shares to the Buyers upon exercise of the Warrants.  The pledge will be evidenced by the Amended
and Restated Pledge Agreement, dated as of the date hereof, by and among the
Company and the Buyers, substantially in the form attached hereto as Exhibit
C (the “Amended and Restated Pledge
Agreement”), and the Amended and Restated Securities Account Control
Agreement, dated as of the date hereof, by and among the Company, the Buyers  and Mellon Investor Services, LLC, as
Custodian (the “Custodian”),
substantially in the form attached hereto as Exhibit D (the “Amended and Restated Securities Account Control
Agreement”);


 


F.              A
portion of the aggregate Purchase Price (as defined below) for the Notes and
the Warrants is being deposited in a secured cash collateral account evidenced
by the Amended and


 

















 


Restated
Pledge Agreement and the Collateral Account Notification and Acknowledgement,
dated as of the date hereof, by and among the Company, the Buyers  and Bank of America Securities LLC, as
Cash Collateral Custodian (the “Cash
Collateral Custodian”), substantially in the form attached hereto as
Exhibit E (the “Cash Collateral
Account Control Agreement”);


 


G.             Contemporaneously
with the execution and delivery of this Agreement, the parties hereto are
executing and delivering a Registration Rights Agreement, substantially in the
form attached hereto as Exhibit F (the “Registration Rights Agreement”),
pursuant to which the Company has agreed to provide certain registration rights
with respect to the Conversion Shares and the Interest Shares under the 1933
Act and the rules and regulations promulgated thereunder, and applicable state
securities laws; and


 


H.            The
Notes, the Conversion Shares, the Interest Shares and the Warrants collectively
are referred to herein as the “Securities”.


 


NOW, THEREFORE, the
Company and each Buyer hereby agree as follows:


 


1.               PURCHASE
AND SALE OF NOTES AND WARRANTS.


 


(a)                                  Purchase
of Notes and Warrants.


 


(i)                                     Notes
and Warrants.  Subject to the
satisfaction (or waiver) of the conditions set forth in Sections 6(a) and 7(a)
below, the Company shall issue and sell to each Buyer, and each Buyer
severally, but not jointly, agrees to purchase from the Company on the Closing
Date (as defined below), a principal amount of Notes, as is set forth opposite
such Buyer’s name in column (3) on the Schedule of Buyers,  along with Warrants to
acquire that number of Warrant Shares as is set forth opposite such Buyer’s
name in column (4) on the Schedule of Buyers.


 


(ii)                                  Closing.  The closing (the “Closing”) of the purchase of
the Notes and the Warrants by the Buyers shall occur at the offices of Schulte
Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022.  The date and time of the Closing (the “Closing Date”)
shall be 10:00 a.m., New York City Time, on the date hereof, subject to
notification of satisfaction (or waiver) of the conditions to the Closing set
forth in Sections 6(a) and 7(a) below (or such later date as is mutually agreed
to by the Company and each Buyer).


 


(iii)                               Purchase
Price.  The purchase price for each
Buyer (the “Purchase Price”) of the Notes and related Warrants to be
purchased by each such Buyer at the Closing shall be equal to $1.00 for each
$1.00 of principal amount of Notes being purchased by such Buyer at the
Closing.


 


(b)                                 Form
of Payment.  On the Closing Date,
(i) each Buyer shall pay half of its aggregate Purchase Price to the Company
for the Notes and the Warrants to be issued and sold to such Buyer at the
Closing and the remaining half of its Purchase Price to the Cash Collateral
Custodian, in both cases by wire transfer of immediately available funds in
accordance with the Company’s written wire instructions, and (ii) the
Company shall deliver to each Buyer the Notes (in the principal amounts as such
Buyer shall have requested prior to the Closing)


 


2

















 


which such Buyer is then
purchasing along with the Warrants (in the amounts as such Buyer shall have
requested prior to the Closing) such Buyer is purchasing, duly executed on
behalf of the Company and registered in the name of such Buyer or its designee.


 


2.               BUYER’S
REPRESENTATIONS AND WARRANTIES.


 


Each Buyer
represents and warrants with respect to only itself that:


 


(a)                                  No
Public Sale or Distribution.  Such
Buyer is (i) acquiring the Notes and the Warrants, and (ii) upon conversion of
the Notes  will acquire the Conversion
Shares issuable upon conversion of the Notes, for its own account and not with
a view towards, or for resale in connection with, the public sale or
distribution thereof, except pursuant to sales registered or exempted under the
1933 Act; provided, however, that by making the representations
herein, such Buyer does not agree to hold any of the Securities for any minimum
or other specific term and reserves the right to dispose of the Securities at
any time in accordance with or pursuant to a registration statement or an
exemption under the 1933 Act.  Such
Buyer is acquiring the Securities hereunder in the ordinary course of its
business.


 


(b)                                 Accredited
Investor Status.  Such Buyer is an
“accredited investor” as that term is defined in Rule 501(a) of Regulation D.


 


(c)                                  Reliance
on Exemptions.  Such Buyer
understands that the Securities are being offered and sold to it in reliance on
specific exemptions from the registration requirements of United States federal
and state securities laws and that the Company is relying in part upon the
truth and accuracy of, and such Buyer’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of such Buyer set
forth herein in order to determine the availability of such exemptions and the
eligibility of such Buyer to acquire the Securities.


 


(d)                           Information.  Such Buyer and its advisors, if any, have
been furnished with all materials relating to the business, finances and
operations of the Company and materials relating to the offer and sale of the
Securities which have been requested by such Buyer.  Such Buyer and its advisors, if any, have been afforded the
opportunity to ask questions of the Company. 
Neither such inquiries nor any other due diligence investigations
conducted by such Buyer or its advisors, if any, or its representatives shall
modify, amend or affect such Buyer’s right to rely on the Company’s representations
and warranties contained herein.


 


(e)                                  Experience
of such Buyer.  Such Buyer
understands that its investment in the Securities involves a high degree of
risk.  Such Buyer, either alone or
together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating
the merits and risks of the prospective investment in the Securities, and has
so evaluated the merits and risks of such investment.  Such Buyer is able to bear the economic risk of an investment in
the Securities and, at the present time, is able to afford a complete loss of
such investment.


 


(f)                                    Tax
Liability.  Such Buyer has sought
such accounting, legal and tax advice as it has considered necessary to make an
informed investment decision with respect to its


 


3

















 


acquisition of the Securities.  With respect to such matters, such Buyer
relies solely on such advisors and not on any statements or representations of
the Company or any of its agents other than the representations and warranties
set forth in the Transaction Documents (as defined in Section 3(b)).  Such Buyer understands that it (and not the
Company) shall be responsible for its own tax liability that may arise as a
result of this investment or the transactions contemplated by the Agreements.


 


(g)                                 General
Solicitation.  Such Buyer is not
purchasing the Securities as a result of any advertisement, article, notice or
other communication regarding the Securities published in any newspaper,
magazine or similar media or broadcast over television or radio or presented at
any seminar or any other general solicitation or general advertisement (as
defined in Regulation D).


 


(h)                                 No
Governmental Review.  Such Buyer understands
that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of
the Securities or the fairness or suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the
offering of the Securities.


 


(i)                                     Transfer
or Resale.  Such Buyer understands
that except as provided in the Registration Rights Agreement: (i) the
Securities have not been and are not being registered under the 1933 Act or any
state securities laws, and may not be offered for sale, sold, assigned or
transferred unless (A) subsequently registered thereunder, (B) such Buyer shall
have delivered to the Company an opinion of counsel, in a form reasonably acceptable
to the Company, to the effect that such Securities to be sold, assigned or
transferred may be sold, assigned or transferred pursuant to an exemption from
such registration, or (C) such Buyer provides the Company with reasonable
assurance that such Securities can be sold, assigned or transferred pursuant to
Rule 144 or Rule 144A promulgated under the 1933 Act, as amended (or a
successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Securities
made in reliance on Rule 144 may be made only in accordance with the terms of
Rule 144 and further, if Rule 144 is not applicable, any resale of the
Securities under circumstances in which the seller (or the Person (as defined
in Section 3(r)) through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the 1933 Act) may require compliance
with some other exemption under the 1933 Act or the rules and regulations of
the SEC thereunder, and may be made only in accordance with such exemption or
rules and regulations; and (iii) neither the Company nor any other Person is
under any obligation to register the Securities under the 1933 Act or any state
securities laws or to comply with the terms and conditions of any exemption
thereunder.  The Securities may be
pledged in connection with a bona fide margin account or other loan or
financing arrangement secured by the Securities and such pledge of Securities
shall not be deemed to be a transfer, sale or assignment of the Securities
hereunder, and no Buyer effecting a pledge of Securities shall be required to
provide the Company with any notice thereof or otherwise make any delivery to
the Company pursuant to this Agreement or any other Transaction Document (as
defined in Section 3(b)), including, without limitation, this Section 2(i); provided,
that in order to make any sale, transfer or assignment of Securities, such
Buyer and its pledgee makes such disposition in accordance with or pursuant to
a registration statement or an exemption under the 1933 Act.


 


4

















 


(j)                                     Legends.  Such Buyer understands that the certificates
or other instruments representing the Notes and the Warrants and, until such
time as the resale of the Conversion Shares have been registered under the 1933
Act as contemplated by the Registration Rights Agreement, the stock
certificates representing the Conversion Shares, except as set forth below,
shall bear any legend as required by the “blue sky” laws of any state and a
restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of such stock certificates):


 


[NEITHER THE
ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE [NOR THE
SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN][THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) AN OPINION OF COUNSEL, IN
A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED
UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR (II) UNLESS SOLD
PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.


 


The legend set forth above
shall be removed and the Company shall issue a certificate without such legend
to the holder of the Securities upon which it is stamped, if, unless otherwise
required by state securities laws, (i) such Securities are registered for
resale under the 1933 Act, provided, however, that each Buyer has
complied with or covenants and agrees that it will comply with the prospectus
delivery requirements of the 1933 Act as applicable to it in connection with
sales of such Securities pursuant to a registration statement, (ii) in
connection with a sale, assignment or other transfer, such holder provides the
Company with an opinion of counsel, in a form reasonably acceptable to the
Company, to the effect that such legend is not required under applicable
requirements of the 1933 Act, or (iii) such holder provides the Company with
reasonable assurance that the Securities can be sold, assigned or transferred
pursuant to Rule 144.


 


(k)                                  Organization;
Validity; Enforcement.  Such Buyer
is an entity duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization with the requisite corporate,
limited liability company or partnership, as applicable, power and authority to
enter into and to consummate the transactions contemplated by the Transaction
Documents to which it is a party and otherwise to carry out its obligations
hereunder and thereunder.  This
Agreement, the Amended and Restated Pledge Agreement, the Registration Rights
Agreement, the Amended and Restated Securities Account Control Agreement and
the


 


5

















 


Cash Collateral Account Control Agreement
have been duly and validly authorized, executed and delivered on behalf of such
Buyer and shall constitute the legal, valid and binding obligations of such
Buyer, enforceable against such Buyer in accordance with their respective
terms, except as such enforceability may be limited by general principles of
equity or to applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation and other similar laws relating to, or affecting generally, the
enforcement of applicable creditors’ rights and remedies and except that the
indemnification provisions under the Registration Rights Agreement may further
be limited by principles of public policy.


 


(l)                                     Residency.  Such Buyer is a resident of that
jurisdiction specified below its address on the Schedule of Buyers.


 


3.               REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.


 


Except as set forth
under the corresponding section of the disclosure schedule supplied by the
Company to each Buyer as of the date of this Agreement (the “Disclosure Schedules”), the Company
represents and warrants to each of the Buyers that:


 


(a)                                  Organization
and Qualification.  The Company and
its “Subsidiaries”
(which for purposes of this Agreement means any entity, other than AVII, in
which the Company, directly or indirectly, owns 10% or more of the capital
stock or holds 10% or more of an equity or similar interest) are corporations
duly organized and validly existing in good standing under the laws of the
jurisdiction in which they are incorporated, and have the requisite corporate
power and authorization to own their properties and to carry on their business
as now being conducted.  Each of the
Company and its Subsidiaries is duly qualified as a foreign corporation to do
business and is in good standing in every jurisdiction in which its ownership
of property or the nature of the business conducted by it makes such
qualification necessary, except to the extent that the failure to be so
qualified or be in good standing would not have a Material Adverse Effect.  As used in this Agreement, “Material
Adverse Effect” means any material adverse effect on the business,
properties, assets, operations, results of operations or condition (financial
or otherwise) of the Company and its Subsidiaries, taken as a whole, or on the
transactions contemplated hereby and the other Transaction Documents or by the
agreements and instruments to be entered into in connection herewith or
therewith, or on the authority or ability of the Company to perform its
obligations under the Transaction Documents. 
The Company has no Subsidiaries except as set forth on Schedule 3(a).  None of such Subsidiaries is material to the
Company.


 


(b)                                 Authorization;
Enforcement; Validity.  The Company
has the requisite corporate power and authority to enter into and perform its
obligations under this Agreement, the Notes, the Registration Rights Agreement,
the Irrevocable Transfer Agent Instructions (as defined in Section 5(b)), the
Warrants, the Amended and Restated Pledge Agreement, the Amended and Restated
Securities Account Control Agreement, the Cash Collateral Account Control
Agreement and each of the other agreements entered into by the parties hereto
in connection with the transactions contemplated by this Agreement
(collectively, the “Transaction Documents”), to issue the
Securities and to pledge and transfer the AVII Shares in accordance with the
terms hereof and thereof.  The execution
and delivery of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby


 


6

















 


and thereby, including, without limitation,
the issuance of the Notes and the Warrants, the reservation for issuance and
the issuance of the Conversion Shares  issuable upon conversion thereof and the
pledging and transfer of the AVII Shares, as the case may be, have been duly
authorized by the Company’s Board of Directors and (other than the Stockholder
Approval pursuant to Section 4(n) for certain issuances that may require such
approval pursuant to the rules of the Nasdaq National Market (the “Principal
Market”)) no further consent or authorization is required by the
Company, its Board of Directors or its stockholders.  This Agreement and the other Transaction Documents of even date
herewith have been duly executed and delivered by the Company, and constitute
the legal, valid and binding obligations of the Company, enforceable against
the Company in accordance with their respective terms, except as such
enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally, the enforcement of applicable creditors’
rights and remedies and except that the indemnification provisions under the
Registration Rights Agreement may further be limited by principles of public
policy.


 


(c)                                  Issuance
of Securities.  The Notes and the
Warrants are duly authorized and, upon issuance in accordance with the terms
hereof, shall be free from all taxes, liens and charges with respect to the
issue thereof.  As of the Closing, a
number of shares of Company Common Stock shall have been duly authorized and
reserved for issuance which equals 130% of the maximum number of shares of
Company Common Stock issuable upon conversion of, or as payment for interest
on, the Notes to be issued at the Closing. 
Upon conversion in accordance with the Notes, and upon issuance of
Interest Shares as interest on the Notes, the Conversion Shares and the
Interest Shares, respectively, will be validly issued, fully paid and
nonassessable and free from all taxes, liens and charges with respect to the
issue thereof, with the holders being entitled to all rights accorded to a
holder of Company Common Stock.  Upon
exercise in accordance with the Warrants, the Warrant Shares, will be free from
all taxes, liens and charges, with the holders being entitled to all rights
accorded to the Company as holder of the AVII Common Stock prior to exercise of
the Warrants.  Assuming the accuracy of
the Buyers representations and warrants set forth in Section 2 hereof, the
issuance by the Company of the Securities is exempt from registration under the
1933 Act.


 


(d)                                 No
Conflicts.  The execution, delivery
and performance of the Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby
(including, without limitation, the issuance of the Notes and Warrants, the
pledge and any transfer of the AVII Shares and reservation for issuance and
issuance of the Conversion Shares and the Interest Shares) will not (i) result
in a violation of the certificate of incorporation, any certificate of
designations, preferences and rights of any outstanding series of preferred
stock or bylaws of the Company or any Subsidiary or (ii) except as disclosed in
Schedule 3(d), conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which the Company or any of its Subsidiaries
is a party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws and regulations
and the rules and regulations of the Principal Market) applicable to the
Company or any of its Subsidiaries or by which any property or asset of the
Company or any of its


 


7

















 


Subsidiaries is bound or affected, except in
the case of each of clauses (ii) and (iii), such as would not, individually or
in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect.


 


(e)                                  Consents.  Other than (i) the filing with the SEC of
the Registration Statement (as defined in the Registration Rights Agreement),
(ii) any filings required pursuant to Section 4(b) hereof, (iii) the
application(s) to the Principal Market for the listing of the Conversion Shares
and Interest Shares for trading thereon and (iv) with respect to the Interest
Shares, any stockholder approval required by the rules of the Principal Market,
the Company is not required to obtain any consent, authorization or order of,
or make any filing or registration with, any court, governmental agency or any
regulatory or self-regulatory agency or any other Person in order for it to
execute, deliver or perform any of its obligations under or contemplated by the
Transaction Documents, in each case in accordance with the terms hereof or
thereof.  Other than the filing with the
SEC of the Registration Statement and with respect to the Interest Shares, any
stockholder approval required by the rules of the Principal Market, all
consents, authorizations, orders, filings and registrations which the Company
is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the Closing Date.  The
Company and its Subsidiaries are unaware of any facts or circumstances which
might reasonably be expected to prevent the Company from obtaining or effecting
any of the registration, application or filings pursuant to the preceding
sentence.  The Company is not in
violation of the listing requirements of the Principal Market.  The Company has no knowledge, without having
undertaken any affirmative independent inquiry of AVII, of any violation by
AVII of the listing requirements of the Principal Market with respect to the
AVII Common Stock.  The Company has no
knowledge, without having undertaken any affirmative independent inquiry of
AVII, of any facts which would reasonably lead to delisting or suspension of
the Company Common Stock or the AVII Common Stock in the foreseeable future.


 


(f)                                    Acknowledgment
Regarding Buyer’s Purchase of Securities. 
The Company acknowledges and agrees that each Buyer is acting solely in
the capacity of arm’s length purchaser with respect to the Transaction
Documents and the transactions contemplated hereby and thereby, and that no
Buyer is (i) an officer or director of the Company, (ii) an “affiliate” of the
Company (as defined in Rule 144) or (iii) to the Company’s knowledge, a “beneficial
owner” of more than 10% of the Company Common Stock (as defined for purposes of
Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “1934 Act”)).  The Company further acknowledges that no Buyer is acting as a
financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated hereby
and thereby, and any advice given by a Buyer or any of its representatives or
agents in connection with the Transaction Documents and the transactions
contemplated hereby and thereby is merely incidental to such Buyer’s purchase
of the Securities.  The Company further
represents to each Buyer that the Company’s decision to enter into the Transaction
Documents has been based solely on the independent evaluation by the Company
and its representatives.


 


(g)                                 No
General Solicitation; Placement Agent’s Fees.  Neither the Company, nor any of its affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation
or general advertising (within the meaning of Regulation D) in connection


 


8

















 


with the offer or sale of the
Securities.  The Company shall be
responsible for the payment of any placement agent’s fees, financial advisory
fees, or brokers’ commissions (other than for persons engaged by any Buyer or
its investment advisor) relating to or arising out of the transactions
contemplated hereby.  The Company shall
pay, and hold each Buyer harmless against, any liability, loss or expense
(including, without limitation, attorney’s fees and out-of-pocket expenses)
arising in connection with any such claim. 
Other than engaging Rodman & Renshaw, Inc. as placement agent (the “Agent”),
the Company has not engaged any placement agent or other agent in connection
with the sale of the Notes and the Warrants.


 


(h)                                 No
Integrated Offering.  None of the
Company, its Subsidiaries, any of their affiliates, and any Person acting on
their behalf has, directly or indirectly, made any offers or sales of any
security or solicited any offers to buy any security, under circumstances that
would require registration of any of the Securities under the 1933 Act or cause
this offering of the Securities to be integrated with prior offerings by the
Company for purposes of the 1933 Act or any applicable stockholder approval
provisions, including, without limitation, under the rules and regulations of
any exchange or automated quotation system on which any of the securities of
the Company are listed or designated. 
None of the Company, its Subsidiaries, their affiliates and any Person
acting on their behalf will take any action or steps referred to in the
preceding sentence that would require registration of any of the Securities
under the 1933 Act or cause the offering of the Securities to be integrated
with other offerings.


 


(i)                                     Dilutive
Effect.  The Company understands and
acknowledges that the number of Conversion Shares issuable upon conversion of
the Notes will increase in certain circumstances.  Subject to the Stockholder Approval requirement, the Company
further acknowledges that its obligation to issue Conversion Shares upon
conversion of the Notes in accordance with this Agreement and the Notes  is,
in each case, absolute and unconditional regardless of the dilutive effect that
such issuance may have on the ownership interests of other stockholders of the
Company.


 


(j)                                     Application
of Takeover Protections; Rights Agreement. 
The Company and its board of directors have taken all necessary action,
if any, in order to render inapplicable any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Certificate of Incorporation
(as defined in Section 3(q)) or the laws of the state of its incorporation
which is or could become applicable to any Buyer as a result of the
transactions contemplated by this Agreement, including, without limitation, the
Company’s issuance of the Securities and any Buyer’s ownership of the
Securities.  The Company has not adopted
a stockholder rights plan or similar arrangement relating to accumulations of
beneficial ownership of Company Common Stock or a change in control of the
Company.


 


(k)                                  SEC
Documents; Financial Statements. 
Since December 31, 2000, the Company has filed all reports, schedules,
forms, statements and other documents required to be filed by it with the SEC
pursuant to the reporting requirements of the 1934 Act (all of the foregoing
filed prior to the date hereof and all exhibits included therein and financial
statements and schedules thereto and documents incorporated by reference
therein being hereinafter referred to as the “SEC Documents”).  The Company has delivered to the Buyers or
their respective representatives true, correct and complete copies of the SEC
Documents not available on the


 


9

















 


EDGAR system.  As of their respective dates, the SEC Documents complied in all
material respects with the requirements of the 1934 Act and the rules and
regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC,
contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were
made, not misleading.  As of their respective
dates, the financial statements of the Company included in the SEC Documents
complied as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC with respect
thereto.  Such financial statements have
been prepared in accordance with generally accepted accounting principles,
consistently applied, during the periods involved (except (i) as may be
otherwise indicated in such financial statements or the notes thereto, or (ii)
in the case of unaudited interim statements, to the extent they may exclude
footnotes or may be condensed or summary statements) and fairly present in all
material respects the financial position of the Company as of the dates thereof
and the results of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit
adjustments).  No other information
provided by or on behalf of the Company to the Buyers which is not included in
the SEC Documents, including, without limitation, information referred to in
Section 2(d) of this Agreement, contains any untrue statement of a material
fact or omits to state any material fact necessary in order to make the
statements therein, in the light of the circumstance under which they are or
were made and, taken together with the information set forth in the SEC
Documents, not misleading.


 


(l)                                     Absence
of Certain Changes.  Since the date
of the most recent quarterly report on Form 10-Q, except as specifically
disclosed in the SEC Documents filed not later than 10 days prior to the date
hereof, there has been no material adverse change and no material adverse
development in the business, properties, operations, condition (financial or
otherwise) or results of operations of the Company or its Subsidiaries.  Since the date of the most recent quarterly
report on Form 10-Q and except as specifically disclosed in the SEC Documents
filed not later than 10 days prior to the date hereof, the Company has not (i)
declared or paid any dividends, (ii) sold any assets, individually or in the
aggregate, in excess of $1,000,000 outside of the ordinary course of business
or (iii) had capital expenditures, individually or in the aggregate, in excess
of $1,000,000.  The Company has not
taken any steps to seek protection pursuant to any bankruptcy law nor does the
Company have any knowledge or reason to believe that its creditors intend to
initiate involuntary bankruptcy proceedings or any actual knowledge of any fact
which would reasonably lead a creditor to do so.  The Company is not as of the date hereof, and after giving effect
to the transactions contemplated hereby to occur at the Closing, will not be
Insolvent (as defined below).  For
purposes of this Section 3(l), “Insolvent” means (i) the present fair
saleable value of the Company’s assets is less than the amount required to pay
the Company’s total indebtedness, contingent or otherwise, (ii) the Company is
unable to pay its debts and liabilities, subordinated, contingent or otherwise,
as such debts and liabilities become absolute and matured or (iii) the Company
intends to incur or believes that it will incur debts that would be beyond its
ability to pay as such debts mature.


 


(m)                               No
Undisclosed Events, Liabilities, Developments or Circumstances.  Except as disclosed in Schedule 3(m),
no event, liability, development or circumstance has


 


10

















 


occurred or exists, or is contemplated to
occur, with respect to the Company or its Subsidiaries or their respective
business, properties, operations or financial condition, that would be required
to be disclosed by the Company under applicable securities laws on a
registration statement on Form S-1 filed with the SEC relating to an issuance
and sale by the Company of the Company Common Stock and which has not been so
disclosed or otherwise publicly announced.


 


(n)                                 Conduct
of Business; Regulatory Permits. 
Neither the Company nor its Subsidiaries is in violation of any term of
or in default under its Certificate of Incorporation, any Certificate of Designations,
Preferences and Rights of any outstanding series of preferred stock of the
Company or Bylaws or their organizational charter or bylaws, respectively.  Neither the Company nor any of its
Subsidiaries is in violation of any judgment, decree or order or any statute,
ordinance, rule or regulation applicable to the Company or its Subsidiaries,
and neither the Company nor any of its Subsidiaries will conduct its business
in violation of any of the foregoing, except for possible violations which would
not, individually or in the aggregate, have a Material Adverse Effect.  Without limiting the generality of the
foregoing, the Company is not in violation of any of the rules, regulations or
requirements of the Principal Market, and has no knowledge of any facts or
circumstances which would reasonably lead to delisting or suspension of the
Company Common Stock by the Principal Market in the foreseeable future.  Since December 31, 2001, (i) the Company
Common Stock has been designated for quotation or listed on the Principal
Market, (ii) trading in the Company Common Stock has not been suspended by the
SEC or the Principal Market, (iii) the Company has received no communication,
written or oral, from the SEC or the Principal Market regarding the suspension or
delisting of the Company Common Stock from the Principal Market, (iv) to the
knowledge of the Company, without having undertaken any affirmative independent
inquiry of AVII, AVII Common Stock has been designated for quotation or listed
on the Principal Market, (v) to the knowledge of the Company, without having
undertaken any affirmative independent inquiry of AVII, trading in AVII Common
Stock has not been suspended by the SEC or the Principal Market and (vi) to the
knowledge of the Company, without having undertaken any affirmative independent
inquiry of AVII, AVII has received no communication, written or oral, from the
SEC or the Principal Market regarding the suspension or delisting of the AVII
Common Stock from the Principal Market. 
The Company and its Subsidiaries possess all certificates,
authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct their respective businesses, except
where the failure to possess such certificates, authorizations or permits would
not have, individually or in the aggregate, a Material Adverse Effect, and
neither the Company nor any such Subsidiary has received any notice of
proceedings relating to the revocation or modification of any such certificate,
authorization or permit.


 


(o)                                 Foreign
Corrupt Practices.  Neither the
Company, nor any of its Subsidiaries, nor, to the knowledge of the Company, any
director, officer, agent, employee or other Person acting on behalf of the
Company or any of its Subsidiaries has, in the course of its actions for, or on
behalf of, the Company (i) used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expenses relating to
political activity; (ii) made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds; (iii)
violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate,


 


11

















 


payoff, influence payment, kickback or other
unlawful payment to any foreign or domestic government official or employee.


 


(p)                           Transactions
With Affiliates.  Except as set
forth on Schedule 3(p) and in the SEC Documents filed at least ten days
prior to the date hereof and other than the grant of stock options disclosed on
Schedule 3(q), none of the officers or directors and, to the knowledge
of the Company, none of the employees of the Company is presently a party to
any transaction with the Company or any of its Subsidiaries (other than for
ordinary course services as employees, officers or directors), including any
contract, agreement or other arrangement providing for the furnishing of
services to or by, providing for rental of real or personal property to or
from, or otherwise requiring payments to or from any such officer, director or
employee or, to the knowledge of the Company, any corporation, partnership,
trust or other entity in which any such officer, director, or employee has a
substantial interest or is an officer, director, trustee or partner.


 


(q)                                 Equity
Capitalization.  As of the date
hereof, the authorized capital stock of the Company consists of (x) 150,000,000
shares of Company Common Stock, of which as of the date hereof, 32,810,830
shares are issued and outstanding, options for the purchase of 5,167,974 shares
outstanding pursuant to the Company’s stock option plan, stock purchase plan
and non plan options, and 6,646,514 shares are issuable pursuant to securities
(other than the aforementioned options, the Notes and the Warrants) exercisable
or exchangeable for, or convertible into, shares of Company Common Stock, and
(y) 2,000,000 shares of preferred stock, of which as of the date hereof, none
are issued and outstanding.  All of such
outstanding shares have been, or upon issuance will be, validly issued and are
fully paid and nonassessable.  Except as
disclosed herein and in Schedule 3(q) and other than the Amended and
Restated Senior Convertible Notes of the Company issued to the Buyers pursuant
to the Conversion and Amendment Agreements (as defined below) (the “February Notes”):  (i) no shares of the Company’s capital stock are subject to
preemptive rights or any other similar rights or any liens or encumbrances
suffered or permitted by the Company; (ii) there are no outstanding
options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, or
exercisable or exchangeable for, any shares of capital stock of the Company or
any of its Subsidiaries, or contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is bound to issue
additional shares of capital stock of the Company or any of its Subsidiaries or
options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, or
exercisable or exchangeable for, any shares of capital stock of the Company or
any of its Subsidiaries; (iii) there are no outstanding debt securities, notes,
credit agreements, credit facilities or other agreements, documents or
instruments evidencing Indebtedness (as defined in Section 3(r)) of the Company
or any of its Subsidiaries or by which the Company or any of its Subsidiaries
is bound; (iv) there are no financing statements securing obligations in any
material amounts, either singly or in the aggregate, filed in connection with
the Company; (v) there are no agreements or arrangements under which the
Company or any of its Subsidiaries is obligated to register the sale of any of
their securities under the 1933 Act (except the Registration Rights Agreement);
(vi) there are no outstanding securities or instruments of the Company or any
of its Subsidiaries which contain any redemption or similar provisions, and
there are no contracts, commitments, understandings or arrangements by which
the Company or any of its Subsidiaries


 


12

















 


is bound to redeem a security of the Company
or any of its Subsidiaries; (vii) there are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by the
issuance of the Securities; (viii) the Company does not have any stock
appreciation rights or “phantom stock” plans or agreements or any similar plan
or agreement; and (ix) the Company and its Subsidiaries have no liabilities or
obligations required to be disclosed in the SEC Documents (as defined herein)
but not so disclosed in the SEC Documents, other than those incurred in the
ordinary course of the Company’s or its Subsidiaries’ respective businesses and
which, individually or in the aggregate, do not or would not have a Material
Adverse Effect.  The Company has
furnished to the Buyer, to the extent not available on the EDGAR system in the
SEC Documents filed at least 10 days prior to the date hereof, true, correct
and complete copies of the Company’s Certificate of Incorporation, as amended
and as in effect on the date hereof (the “Certificate of Incorporation”), and the
Company’s Bylaws, as amended and as in effect on the date hereof (the “Bylaws”),
and the terms of all securities convertible into, or exercisable or
exchangeable for, Company Common Stock and the material rights of the holders
thereof in respect thereto.


 


(r)                                    Indebtedness
and Other Contracts.  Except as
disclosed in Schedule 3(r) and other than the February Notes, neither
the Company nor any of its Subsidiaries (i) has any outstanding Indebtedness
(as defined below), (ii) is a party to any contract, agreement or instrument,
the violation of which, or default under which, by the other party(ies) to such
contract, agreement or instrument would result in a Material Adverse Effect,
(iii) is in violation of any term of or in default under any contract,
agreement or instrument relating to any Indebtedness, except where such
violations and defaults would not result, individually or in the aggregate, in
a Material Adverse Effect, or (iv) is a party to any contract, agreement or
instrument relating to any Indebtedness, the performance of which, in the
judgment of the Company’s officers, has or is expected to have a Material
Adverse Effect.  Schedule 3(r)
provides a detailed description of the material terms of any such outstanding
Indebtedness.  For purposes of this
Agreement:  (x) “Indebtedness” of any Person
means, without duplication (A) all indebtedness for borrowed money, (B) all
obligations issued, undertaken or assumed as the deferred purchase price of
property or services (other than trade payables entered into in the ordinary
course of business), (C) all reimbursement or payment obligations with respect
to letters of credit, surety bonds and other similar instruments, (D) all
obligations evidenced by notes, bonds, debentures or similar instruments,
including obligations so evidenced incurred in connection with the acquisition
of property, assets or businesses, (E) all indebtedness created or arising
under any conditional sale or other title retention agreement, or incurred as
financing, in either case with respect to any property or assets acquired with
the proceeds of such indebtedness (even though the rights and remedies of the
seller or bank under such agreement in the event of default are limited to
repossession or sale of such property), (F) all monetary obligations under any
leasing or similar arrangement which, in connection with generally accepted
accounting principles, consistently applied for the periods covered thereby, is
classified as a capital lease, (G) all indebtedness referred to in clauses (A)
through (F) above secured by (or for which the holder of such Indebtedness has
an existing right, contingent or otherwise, to be secured by) any mortgage,
lien, pledge, charge, security interest or other encumbrance (each, a “Lien”)
upon or in any property or assets (including accounts and contract rights)
owned by any Person, even though the Person which owns such assets or property
has not assumed or become liable for the payment of such indebtedness, and (H)
all Contingent Obligations in respect of indebtedness or


 


13

















 


obligations of others of the kinds referred
to in clauses (A) through (G) above; (y) “Contingent Obligation” means, as to any Person,
any direct or indirect liability, contingent or otherwise, of that Person with
respect to any indebtedness, lease, dividend or other obligation of another
Person if the primary purpose or intent of the Person incurring such liability,
or the primary effect thereof, is to provide assurance to the obligee of such
liability that such liability will be paid or discharged, or that any
agreements relating thereto will be complied with, or that the holders of such
liability will be protected (in whole or in part) against loss with respect
thereto; and (z) “Person” means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated
organization and a government or any department or agency thereof.


 


(s)                                  Absence
of Litigation.  There is no action,
suit, proceeding, inquiry or investigation before or by the Principal Market,
any court, public board, government agency, self-regulatory organization or
body pending or, to the knowledge of the Company, threatened against or
affecting the Company, the Company Common Stock or any of the Company’s
Subsidiaries or any of the Company’s or the Company’s Subsidiaries’ officers or
directors in their capacities as such, except as set forth in Schedule 3(s).


 


(t)                                    Insurance.  The Company and each of its Subsidiaries are
insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as management of the Company believes to be
prudent and customary in the businesses in which the Company and its
Subsidiaries are engaged.  Neither the
Company nor any such Subsidiary has been refused any insurance coverage sought
or applied for and neither the Company nor any such Subsidiary has any reason
to believe that it will not be able to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a cost that would not
have a Material Adverse Effect.


 


(u)                                 Employee
Relations. (i) Neither the Company nor any of its Subsidiaries is a party
to any collective bargaining agreement or employs any member of a union.  The Company and its Subsidiaries believe
that their relations with their employees are good.  No executive officer of the Company (as defined in Rule 501(f) of
the 1933 Act) has notified the Company that such officer intends to leave the
Company or otherwise terminate such officer’s employment with the Company.  No executive officer of the Company, to the
knowledge of the Company, is, or is now expected to be, in violation of any
material term of any employment contract, confidentiality, disclosure or
proprietary information agreement, non-competition agreement, or any other
contract or agreement or any restrictive covenant, and the continued employment
of each such executive officer does not subject the Company or any of its
Subsidiaries to any liability with respect to any of the foregoing matters.


 


(ii)                                  The
Company and its Subsidiaries are in compliance with all federal, state, local and
foreign laws and regulations respecting employment and employment practices,
terms and conditions of employment and wages and hours, except where failure to
be in compliance would not, either individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect.


 


14

















 


(v)                                 Title.  The Company and its Subsidiaries have good
and marketable title in fee simple to all real property and good and marketable
title to all personal property owned by them which is material to the business
of the Company and its Subsidiaries, in each case free and clear of all liens,
encumbrances and defects except such as are described in Schedule 3(v)
or such as do not materially affect the value of such property and do not
interfere in any material respect with the use made and proposed to be made of
such property by the Company and any of its Subsidiaries.  Any real property and facilities held under
lease by the Company and any of its Subsidiaries are held by them under valid,
subsisting and enforceable leases with such exceptions as are not material and
do not interfere with the use made and proposed to be made of such property and
buildings by the Company and its Subsidiaries.


 


(w)                               Intellectual
Property Rights.  The Company and
its Subsidiaries own or possess adequate rights or licenses to use all
trademarks, trade names, service marks, service mark registrations, service
names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and other intellectual property
rights (“Intellectual
Property Rights”) necessary to conduct their respective businesses
as now conducted and which the failure to so own or possess could, individually
or in aggregate, have reasonably be expected to result in a Material Adverse
Effect.  None of the Company’s material
Intellectual Property Rights have expired or terminated or are expected to
expire or terminate within two years from the date of this Agreement.  The Company does not have any knowledge of
any infringement by the Company or its Subsidiaries of Intellectual Property
Rights of others.  There is no claim,
action or proceeding being made or brought, or to the knowledge of the Company,
being threatened, against the Company or its Subsidiaries regarding its
Intellectual Property Rights.  The
Company is unaware of any facts or circumstances which would reasonably be
expected to give rise to any of the foregoing infringements or claims, actions
or proceedings.  The Company and its
Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties.


 


(x)                                   Environmental
Laws.  The Company and its
Subsidiaries (i) are in compliance with any and all Environmental Laws (as
hereinafter defined), (ii) have received all permits, licenses or other
approvals required of them under applicable Environmental Laws to conduct their
respective businesses and (iii) are in compliance with all terms and conditions
of any such permit, license or approval where, in each of the foregoing clauses
(i), (ii) and (iii), the failure to so comply could be reasonably expected to
have, individually or in the aggregate, a Material Adverse Effect.  The term “Environmental Laws” means all
federal, state, local or foreign laws relating to pollution or protection of
human health or the environment (including, without limitation, ambient air,
surface water, groundwater, land surface or subsurface strata), including,
without limitation, laws relating to emissions, discharges, releases or
threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, “Hazardous Materials”)  into
the environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands or
demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations issued, entered, promulgated or approved
thereunder.


 


15

















 


(y)                                 Tax
Status.  The Company and each of its
Subsidiaries (i) has made or filed all federal and state income and all other
tax returns, reports and declarations required by any jurisdiction to which it
is subject, (ii) has paid all taxes and other governmental assessments and
charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith
and (iii) has set aside on its books provision reasonably adequate for the
payment of all taxes for periods subsequent to the periods to which such
returns, reports or declarations apply. 
There are no unpaid taxes in any material amount claimed to be due by
the taxing authority of any jurisdiction, and the officers of the Company know
of no basis for any such claim.


 


(z)                                   Internal
Accounting Controls.  The Company
and each of its Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed
in accordance with management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to
maintain asset and liability accountability, (iii) access to assets or
incurrence of liabilities is permitted only in accordance with management’s
general or specific authorization and (iv) the recorded accountability for
assets and liabilities is compared with the existing assets and liabilities at
reasonable intervals and appropriate action is taken with respect to any
difference.


 


(aa)                            Investment
Company.  The Company is not, and
upon consummation of the sale of the Securities will not be, and is not an
affiliate of, an “investment company” within the meaning of the Investment
Company Act of 1940, as amended.


 


(bb)                          Form
S-3 Eligibility.  The Company is
eligible to register the Company Common Stock for resale by the Buyers under
Form S-3 promulgated under the 1933 Act.


 


(cc)                            AVII
Common Stock.


 


(i)                                     The
transfer of the AVII Shares by the Company have been registered by AVII under
the 1933 Act.  1,000,000 of the AVII
Shares were registered by AVII pursuant to a registration statement filed on
Form S-3 on December 21, 1999, as amended on January 25, 2000, and 1,684,211 of
the AVII Shares were registered by AVII pursuant to a registration statement
filed on Form S-3 on September 15, 2000 (the “AVII Registration Statements”).  The “Plan of Distribution” section under
each of the AVII Registration Statements permits the pledge and transfer of the
AVII Shares as required pursuant to the Transaction Documents.


 


(ii)                                  The
Company is the beneficial and record owner of all of the AVII Shares, free and
clear of any Liens, and upon transfer in accordance with the applicable
Transaction Documents, the Company will transfer to the Buyers good and
marketable title to such AVII Shares, free and clear of any Liens.  Upon any such transfer in accordance with
the applicable Transaction Documents to the Buyers of any AVII Shares, the AVII
Shares shall be unrestricted and freely tradable on the Principal Market without
any delivery or other requirements whatsoever and without the need to make any
registration or other filing with the SEC.


 


16

















 


(iii)                               After
giving effect to the transactions contemplated by the Conversion and Amendment
Agreements, the Company has no legal obligation, absolute or contingent, to any
other Person to transfer or sell any of the AVII Shares.  There is no action, claim, suit,
investigation or proceeding pending or, to the knowledge of the Company,
threatened by or against or affecting the Company or the Company’s ownership of
the AVII Shares before any court or governmental or regulatory authority or
body, that could effect the ability of the Company to pledge and transfer to
the Buyers any AVII Shares.  There are
no writs, decrees, injunctions or orders of any court or governmental or
regulatory agency, authority or body outstanding against the Company with
respect to the AVII Shares.


 


4.               COVENANTS.


 


(a)                                  Best
Efforts.  Each party shall use its
best efforts timely to satisfy each of the conditions to be satisfied by it as
provided in Sections 6 and 7 of this Agreement.


 


(b)                                 Form
D and Blue Sky.  The Company agrees
to file a Form D with respect to the Securities as required under Regulation D
and to provide a copy thereof to each Buyer promptly after such filing.  The Company shall, on or before the Closing
Date, take such action as the Company shall reasonably determine is necessary
in order to obtain an exemption for or to qualify the Securities for sale to
the Buyers at the Closing pursuant to this Agreement under applicable
securities or “Blue Sky” laws of the states of the United States (or to obtain
an exemption from such qualification), and shall provide evidence of any such
action so taken to the Buyers on or prior to the Closing Date.  The Company shall make all filings and
reports relating to the offer and sale of the Securities required under
applicable securities or “Blue Sky” laws of the states of the United States
following the Closing Date.


 


(c)                                  Reporting
Status.  Except as set forth in
Section 5 of the Notes, until the date on which the Investors (as defined in
the Registration Rights Agreement) shall have sold all the Conversion Shares
and Interest Shares and none of the Notes is outstanding (the “Reporting
Period”), the Company shall file all reports required to be filed
with the SEC pursuant to the 1934 Act, and the Company shall not terminate its
status as an issuer required to file reports under the 1934 Act even if the
1934 Act or the rules and regulations thereunder would otherwise permit such
termination.


 


(d)                                 Use
of Proceeds.  The Company will use
the proceeds from the sale of the Securities for working capital purposes and
not for the (i) repayment of any outstanding Indebtedness of the Company or any
of its Subsidiaries or (ii) redemption or repurchase of any of its equity
securities.


 


(e)                                  Financial
Information.  The Company agrees to
send the following to each Investor during the Reporting Period (i) unless the
following are filed with the SEC through EDGAR and are available to the public
through the EDGAR system, within one (1) Business Day after the filing thereof
with the SEC, a copy of its Annual Reports on Form 10-K, its Quarterly Reports
on Form 10-Q, any Current Reports on Form 8-K and any registration statements
(other than on Form S-8) or amendments filed pursuant to the 1933 Act, (ii) on
the same day as the release thereof, facsimile copies of all press releases
issued by the Company or any of its Subsidiaries, and (iii) copies of any
notices and other information made available or


 


17

















 


given to the stockholders of the Company
generally, contemporaneously with the making available or giving thereof to the
stockholders.  As used herein, “Business
Day” means any day other than Saturday, Sunday or other day on which
banking institutions in The City of New York are authorized or required by law
to remain closed.


 


(f)                                    Listing.  The Company shall promptly secure the
listing of all of the Registrable Securities (as defined in the Registration
Rights Agreement) upon each national securities exchange and automated
quotation system, if any, upon which shares of Company Common Stock are then
listed (subject to official notice of issuance) and shall maintain, so long as
any other shares of Company Common Stock shall be so listed, such listing of
all Registrable Securities from time to time issuable under the terms of the
Transaction Documents.  The Company
shall maintain the Company Common Stock’s authorization for quotation on the
Principal Market.  Neither the Company
nor any of its Subsidiaries shall take any action which would be reasonably
expected to result in the delisting or suspension of the Company Common Stock
on the Principal Market.  The Company
shall pay all fees and expenses in connection with satisfying its obligations
under this Section 4(f).


 


(g)                                 Fees.  Subject to Section 8 below, at the Closing,
the Company shall pay an expense allowance of $69,000 to Smithfield Fiduciary
LLC (a Buyer) or its designee(s) for reimbursement of reasonable legal and due
diligence expenses incurred in connection with the transactions contemplated by
the Transaction Documents, which amount shall be withheld by such Buyer from
its Purchase Price at the Closing.  The
Company shall be responsible for the payment of any placement agent’s fees or
broker’s commissions relating to or arising out of the transactions
contemplated hereby, including, without limitation, any fees or commissions
payable to the Agent.  The Company shall
pay, and hold each Buyer harmless against, any liability, loss or expense
(including, without limitation, reasonable attorney’s fees and out-of-pocket
expenses) arising in connection with any claim relating to any such
payment.  Except as otherwise set forth
in the Transaction Documents, each party to this Agreement shall bear its own
expenses in connection with the sale of the Securities to the Buyers.


 


(h)                                 Pledge
of Securities.  The Company
acknowledges and agrees that the Securities may be pledged by an Investor (as
defined in the Registration Rights Agreement) in connection with a bona fide
margin agreement or other loan or financing arrangement that is secured by the
Securities.  The pledge of Securities
shall not be deemed to be a transfer, sale or assignment of the Securities
hereunder, and no Investor effecting a pledge of Securities shall be required
to provide the Company with any notice thereof or otherwise make any delivery
to the Company pursuant to this Agreement or any other Transaction Document,
including, without limitation, Section 2(i) of this Agreement; provided that an
Investor and its pledgee shall be required to comply with the provisions of
Section 2(i) hereof in order to effect a sale, transfer or assignment of
Securities to such pledgee.  At the appropriate
Buyer’s expense, the Company shall execute and deliver such reasonable
documentation as a pledgee of the Securities may reasonably request in
connection with a pledge of the Securities to such pledgee by an Investor.


 


(i)                                     Disclosure
of Transactions and Other Material Information.  On or before 8:30 a.m., New York City Time, on  the
first Trading Day following the date hereof, the Company shall file a Current
Report on Form 8-K describing the terms of the transactions contemplated by the
Transaction Documents in the form required by the 1934 Act, and attaching


 


18

















 


the material Transaction Documents
(including, without limitation, this Agreement (and all schedules to this
Agreement), the form of each of the Notes, the form of Warrant, the Amended and
Restated Pledge Agreement, the Amended and Restated Securities Account Control
Agreement, the Cash Collateral Account Control Agreement  and the Registration Rights
Agreement) as exhibits to such Form 8-K (including all attachments, the “8-K Filing”).  From and after the filing of the 8-K Filing
with the SEC, unless required pursuant to Section 3(i) of the Registration
Rights Agreement, no Buyer shall be in possession of any material, nonpublic
information received from the Company, any of its Subsidiaries or any of its
respective officers, directors, employees or agents, that is not disclosed in
the 8-K Filing.  Unless required
pursuant to Section 3(i) of the Registration Rights Agreement, the Company
shall not, and shall cause each of its Subsidiaries and its and each of their
respective officers, directors, employees and agents, not to, provide any Buyer
with any material nonpublic information regarding the Company or any of its
Subsidiaries from and after the filing of the 8-K Filing with the SEC without
the express written consent of such Buyer. 
In the event of a breach of the foregoing covenant by the Company, any
of its Subsidiaries, or any of its or their respective officers, directors,
employees and agents, in addition to any other remedy provided herein or in the
Transaction Documents, a Buyer shall have the right to make a public
disclosure, in the form of a press release, public advertisement or otherwise,
of such material nonpublic information without the prior approval by the
Company, its Subsidiaries, or any of its or their respective officers,
directors, employees or agents.  No
Buyer shall have any liability to the Company, its Subsidiaries, or any of its
or their respective officers, directors, employees, stockholders or agents for
any such disclosure.  Subject to the
foregoing, neither the Company nor any Buyer shall issue any press releases or
any other public statements with respect to the transactions contemplated
hereby; provided, however, that the Company shall be entitled,
without the prior approval of any Buyer, to make any press release or other
public disclosure with respect to such transactions (i) in substantial
conformity with the 8-K Filing and contemporaneously therewith and (ii) as is
required by applicable law and regulations (provided that in the case of clause
(i) the Buyers shall be consulted by the Company in connection with any such
press release or other public disclosure prior to its release).


 


(j)                                     Restriction
on Redemption and Cash Dividends. 
So long as any Notes are outstanding, the Company shall not, directly or
indirectly, redeem, or declare or pay any cash dividend or distribution on, the
Company Common Stock without the prior express written consent of the holders
of Notes representing not less than a majority of the aggregate principal
amount of the then outstanding Notes.


 


(k)                                  Additional
Notes.  For so long as any Buyer
beneficially owns any Securities, the Company will not issue any additional
Notes and, except as described in Schedule 4(k), the Company shall not issue
any other securities that would cause a breach or default under the Notes.  Each Buyer expressly acknowledges that the
issuance of the Notes shall not be deemed a breach of the terms of the
securities purchase agreement relating to the February Notes.


 


(l)                                     Conduct
of Business.  So long as any Notes
are outstanding, the business of the Company and its Subsidiaries shall not be
conducted in violation of any law, ordinance or


 


19

















 


regulation of any governmental entity, except
where such violations would not result, either individually or in the
aggregate, in a Material Adverse Effect.


 


(m)                               Variable
Securities.  So long as any Notes
are outstanding, the Company shall not, in any manner, issue or sell any
rights, warrants or options to subscribe for or purchase Company Common Stock
or directly or indirectly convertible into or exchangeable or exercisable for
Company Common Stock at a price which varies or may vary with the market price
of the Company Common Stock, including by way of one or more reset(s) to any
fixed price unless the conversion, exchange or exercise price of any such
security cannot be less than the then applicable Conversion Price (as defined in
the Notes) with respect to the Company Common Stock under any Note.


 


(n)                                 Proxy
Statement.  The Company shall
provide each stockholder entitled to vote at the next meeting of stockholders
of the Company, which shall not be later than December 15, 2003 (the “Stockholder
Meeting Deadline”), a proxy statement, which has been previously
reviewed by the Buyers and a counsel of their choice, soliciting each such
stockholder’s affirmative vote at such stockholder meeting for approval of the
Company’s issuance of all of the Securities as described in the Transaction
Documents in accordance with applicable law and the rules and regulations of
the Principal Market (such affirmative approval being referred to herein as the
“Stockholder
Approval”), and the Company shall use its best efforts to solicit
its stockholders’ approval of such issuance of the Securities and to cause the
Board of Directors of the Company to recommend to the stockholders that they
approve such proposal.  The Company
shall be obligated to seek to obtain the Stockholder Approval by the
Stockholder Meeting Deadline.


 


(o)                                 Corporate
Existence.  So long as any Buyer
beneficially owns any Notes, the Company shall maintain its corporate existence
and shall not sell all or substantially all of the Company’s assets, except in
the event of a merger or consolidation or sale of all or substantially all of
the Company’s assets, where the surviving or successor entity in such
transaction (i) assumes the Company’s obligations hereunder and under the
agreements and instruments entered into in connection herewith and (ii) is a
publicly traded corporation whose common stock is quoted on or listed for
trading on the Principal Market or The New York Stock Exchange, Inc.


 


(p)                                 Incurrence
of Liens.  So long as any Notes are
outstanding, the Company shall not, directly or indirectly, allow or suffer to
exist any Lien (other than in connection with the February Notes), other than
Permitted Liens (as defined in the Notes), upon any property or assets
(including accounts and contract rights) owned by the Company.


 


(q)                                 Reservation
of Shares.  The Company shall take
all action necessary to at all times have authorized, and reserved for the
purpose of issuance, no less than 130% of the number of shares of Company
Common Stock issuable upon conversion of, or as payment for interest on, the
Notes.


 


(r)                                    AVII.  At the Closing, the Company shall deliver to
each Buyer a true, correct and complete copy of each prospectus pursuant to the
AVII Registration Statements.  Any
transfer of the AVII Shares by the Company to the Buyers shall be made pursuant
to the AVII Registration Statements, Rule 144(k) or other method acceptable to
holders of at least a


 


20

















 


majority of the aggregate principal amount
the Notes then outstanding.  The Company
hereby agrees to use its reasonable best efforts to cause AVII (i) unless Rule
144(k) is available and to be used in order to transfer the AVII Shares by the
Company to the Buyers, until the date that the Company shall have transferred
the AVII Shares to the Buyers or none of the Warrants is outstanding, to keep
each AVII Registration Statement continuously effective under the 1933 Act and,
if and when the Company deems it necessary, use reasonable best efforts to
cause AVII to file one or more prospectus supplements pursuant to Rule 424(b)
and (ii) so long as any other shares of AVII Common Stock shall be listed on
the Principal Market, to maintain the authorization for quotation on the
Principal Market of the AVII Shares. 
The Company shall take all actions necessary such that the AVII Shares
shall remain free of any Lien.


 


(s)                                  Transfer
of AVII Shares.  Upon transfer of
any AVII Shares to a Buyer pursuant to the terms of the Transaction Documents,
the Company shall take all actions necessary to transfer to Buyer, in
accordance with the applicable terms of the Transaction Documents, the AVII
Shares free and clear of all Liens or restrictions such that after such
transfer the AVII Shares will be unrestricted and freely tradable by the
Buyer.  In connection with the
foregoing, the Company shall (i) cause Wilson, Sonsini, Goodrich & Rosati,
PC or other counsel reasonably acceptable to holders of Notes representing at
least a majority of the aggregate principal amount of the Notes then
outstanding to deliver to the transfer agent of AVII any necessary legal
opinion, and (ii) use reasonable best efforts to take any other actions
reasonably requested by any Buyer in connection with any such transfer.


 


(t)                                    Additional
Issuances of Securities.


 


(i)                                     For
purposes of this Section 4(t), the following definitions shall apply.


 


(1)                                  “Common Stock
Equivalents” means, collectively, Options and Convertible
Securities.


 


(2)                                  “Convertible
Securities” means any stock or securities (other than Options)
convertible into or exercisable or exchangeable for Common Stock.


 


(3)                                  “Options” means any rights, warrants or
options to subscribe for or purchase Common Stock or Convertible Securities.


 


(ii)                                  From
the date hereof until the date the Registration Statement contemplated by the
Registration Rights Agreement is declared effective (the “Effective Date”), the Company will not,
directly or indirectly, offer, sell, grant any option to purchase, or otherwise
dispose of (or announce any offer, sale, grant or any option to purchase or
other disposition of) any of its or the Subsidiaries’ equity or equity
equivalent securities, including without limitation any debt, preferred stock
or other instrument or security that is, at any time during its life and under
any circumstances, convertible into or exchangeable or exercisable for Common
Stock or Common Stock Equivalents (any such offer, sale, grant, disposition or
announcement being referred to as a “Subsequent
Placement”).


 


21

















 


(iii)                               From
the Effective Date until no Notes are outstanding, the Company will not,
directly or indirectly, effect any Subsequent Placement unless the Company
shall have first complied with this Section 4(t)(iii).


 


(1)                                  The
Company shall deliver to each Buyer a written notice (the “Offer”) of any proposed or intended
issuance or sale or exchange of the securities being offered (the “Offered Securities”) in a Subsequent
Placement, which Offer shall (w) identify and describe the Offered Securities,
(x) describe the price and other terms upon which they are to be issued, sold
or exchanged, and the number or amount of the Offered Securities to be issued,
sold or exchanged, (y) identify the persons or entities (if known) to which or
with which the Offered Securities are to be offered, issued, sold or exchanged
and (z) offer to issue and sell to or exchange with Buyers a pro rata portion
of the greater of (A) one-third (1/3rd) of the Offered Securities
and (B) $5,000,000, in each case allocated among the Buyers (a) based on such
Buyer’s pro rata portion of the aggregate principal amount of the Notes
purchased hereunder (the “Basic Amount”),
and (b) with respect to each Buyer that elects to purchase its Basic Amount,
any additional portion of the Offered Securities attributable to the Basic
Amounts of other Buyers as such Buyer shall indicate it will purchase or
acquire should the other Buyers subscribe for less than their Basic Amounts
(the “Undersubscription Amount”).


 


(2)                                  To
accept an Offer, in whole or in part, a Buyer must deliver a written notice to
the Company prior to the end of the five (5) Trading Day period of the Offer
(the “Offer
Period”), setting forth the portion of the Buyer’s Basic Amount that
such Buyer elects to purchase and, if such Buyer shall elect to purchase all of
its Basic Amount, the Undersubscription Amount, if any, that such Buyer elects
to purchase (in either case, the “Notice of
Acceptance”).  If the Basic
Amounts subscribed for by all Buyers are less than the total of all of the
Basic Amounts, then each Buyer who has set forth an Undersubcription Amount in
its Notice of Acceptance shall be entitled to purchase, in addition to the
Basic Amounts subscribed for, the Undersubscription Amount it has subscribed
for; provided, however, that if the Undersubscription Amounts
subscribed for exceed the difference between the total of all the Basic Amounts
and the Basic Amounts subscribed for (the “Available
Undersubscription Amount”), each Buyer who has subscribed for any
Undersubscription Amount shall be entitled to purchase only that portion of the
Available Undersubscription Amount as the Basic Amount of such Buyer bears to
the total Basic Amounts of all Buyers that have subscribed for
Undersubscription Amounts, subject to rounding by the Board of Directors to the
extent its deems reasonably necessary.


 


(3)                                  The
Company shall have five (5) Trading Days from the expiration of the Offer
Period above to offer, issue, sell or exchange all or any part of such Offered
Securities as to which a Notice of Acceptance has not been given by the Buyers
(the “Refused Securities”), but
only to the offerees described in the Offer (if so described therein) and only
upon terms and conditions (including, without limitation, unit prices and
interest rates) that are not more favorable to the acquiring person or persons
or less favorable to the Company than those set forth in the Offer.


 


(4)                                  In
the event the Company shall propose to sell less than all the Refused
Securities (any such sale to be in the manner and on the terms specified in
Section 4(t)(iii)(3) above), then each Buyer may, at its sole option and in its
sole discretion, reduce the


 


22

















 


number or
amount of the Offered Securities specified in its Notice of Acceptance to an
amount that shall be not less than the number or amount of the Offered
Securities that the Buyer elected to purchase pursuant to Section 4(t)(iii)(2)
above multiplied by a fraction, (i) the numerator of which shall be the number or
amount of Offered Securities the Company actually proposes to issue, sell or
exchange (including Offered Securities to be issued or sold to Buyers pursuant
to Section 4(t)(iii)(3) above prior to such reduction) and (ii) the denominator
of which shall be the original amount of the Offered Securities.  In the event that any Buyer so elects to
reduce the number or amount of Offered Securities specified in its Notice of
Acceptance, the Company may not issue, sell or exchange more than the reduced
number or amount of the Offered Securities unless and until such securities
have again been offered to the Buyers in accordance with Section 4(t)(iii)(1)
above.


 


(5)                                  Upon
the closing of the issuance, sale or exchange of all or less than all of the
Refused Securities, the Buyers shall acquire from the Company, and the Company
shall issue to the Buyers, the number or amount of Offered Securities specified
in the Notices of Acceptance, as reduced pursuant to Section 4(t)(iii)(3) above
if the Buyers have so elected, upon the terms and conditions specified in the
Offer.  The purchase by the Buyers of
any Offered Securities is subject in all cases to the preparation, execution
and delivery by the Company and the Buyers of a purchase agreement relating to
such Offered Securities reasonably satisfactory in form and substance to the
Buyers and their respective counsel.


 


(6)                                  Any
Offered Securities not acquired by the Buyers or other persons in accordance
with Section 4(t)(iii)(3) above may not be issued, sold or exchanged until they
are again offered to the Buyers under the procedures specified in this
Agreement.


 


(iv)                              The
restrictions contained in subsections (ii) and (iii) of this Section 4(t) shall
not apply to (1) any issuance of Common Stock or grant of Options to employees,
officers, directors of or consultants or advisors to the Company, in each case,
pursuant to a stock-based plan duly approved by the Company’s board of
directors; (2) upon exercise, conversion or exchange of the Notes, the Separate
Notes (as defined in the Notes) and any warrants to purchase Common Stock
issued to the Buyers on February 26, 2003; (3) the issuance of securities
pursuant to the Company’s bona fide acquisition of another corporation, or all
or a portion of its assets, by merger, purchase of assets or other corporate
reorganization in each case, as approved by the Company’s board of directors
and not for the principal purpose of raising cash, or (4) the issuance of
securities in connection with a joint venture or development agreement or
strategic partnership or similar agreement approved by the Company’s board of
directors, a primary purpose of which is not to raise equity capital.


 


(u)                                 Investor Covenant. 
With respect to the Cash Collateral Account Control Agreement, each
Buyer acknowledges that it is entitled to order or instruct the Cash Collateral
Custodian with respect to the sale, transfer or redemption of all or part of
the Cash Collateral (as such term is defined in the Cash Collateral Account
Control Agreement) and the remittance of proceeds thereof, if any, to such
Buyer; provided  however, that each Buyer hereby agrees that any
such order or instruction that it may issue to the Cash Collateral Custodian
shall be made only once and solely with respect to such Buyer’s pro rata share
of the amount thereof (based on the original amount of Cash Collateral plus all
interest, dividends and earnings with respect thereto).


 


23

















 


5.               REGISTER;
TRANSFER AGENT INSTRUCTIONS.


 


(a)                                  Register.  The Company shall maintain at its principal
executive offices (or such other office or agency of the Company as it may
designate by notice to each holder of Notes or Warrants), a register for the
Notes and the Warrants, in which the Company shall record the name and address
of the Person in whose name the Notes  and the Warrants have been issued
(including the name and address of each transferee), the principal amount of
Notes held by such Person and the number of Warrant Shares issuable upon
exercise of the Warrants held by such Person. 
The Company shall keep the register open and available during business
hours for inspection by any Buyer or its legal representatives upon prior
written notice.


 


(b)                                 Transfer
Agent Instructions.  The Company
shall issue irrevocable instructions to its transfer agent, and any subsequent
transfer agent, to issue certificates or credit shares to the applicable
balance accounts at The Depository Trust Company (“DTC”), registered in the name
of each Buyer or its respective nominee(s), for the Conversion Shares and the
Interest Shares, if any  in such amounts as specified from time to
time by each Buyer to the Company upon conversion of the Notes in the form of Exhibit
G attached hereto (the “Irrevocable Transfer Agent Instructions”).  The Company warrants that no instruction
other than the Irrevocable Transfer Agent Instructions referred to in this
Section 5(b), and stop transfer instructions to give effect to Section 2(j)
hereof, will be given by the Company to its transfer agent, and that the Securities
shall otherwise be freely transferable on the books and records of the Company
as and to the extent provided in this Agreement and the other Transaction
Documents.  If a Buyer effects a sale,
assignment or transfer of the Securities in accordance with Section 2(i), the
Company shall permit the transfer and shall promptly instruct its transfer
agent to issue one or more certificates or credit shares to the applicable
balance accounts at DTC in such name and in such denominations as specified by
such Buyer to effect such sale, transfer or assignment.  In the event that such sale, assignment or
transfer involves Conversion Shares or Interest Shares sold, assigned or
transferred pursuant to an effective registration statement or pursuant to Rule
144, the transfer agent shall issue such Securities to the Buyer, assignee or
transferee, as the case may be, without any restrictive legend.  The Company acknowledges that a breach by it
of its obligations hereunder will cause irreparable harm to a Buyer.  Accordingly, the Company acknowledges that
the remedy at law for a breach of its obligations under this Section 5(b) will
be inadequate and agrees, in the event of a breach or threatened breach by the
Company of the provisions of this Section 5(b), that a Buyer shall be entitled,
in addition to all other available remedies, to an order and/or injunction
restraining any breach and requiring immediate issuance and transfer, without
the necessity of showing economic loss and without any bond or other security
being required.


 


6.               CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.


 


(a)                                  Closing
Date.  The obligation of the Company
hereunder to issue and sell the Notes  and the related Warrants to each Buyer at
the Closing is subject to the satisfaction, at or before the Closing Date, of
each of the following conditions, provided that these conditions are for the
Company’s sole benefit and may be waived by the Company at any time in its sole
discretion by providing each Buyer with prior written notice thereof:


 


24

















 


(i)                                     Such
Buyer shall have executed each of the Transaction Documents to which it is a
party and delivered the same to the Company.


 


(ii)                                  Such
Buyer shall have delivered to the Company the Purchase Price (less, in the case
of Smithfield Fiduciary LLC, the amounts withheld pursuant to Section 4(g)) for
the Notes and the related Warrants being purchased by such Buyer at the Closing
by wire transfer of immediately available funds pursuant to the wire
instructions provided by the Company.


 


(iii)                               The
representations and warranties of such Buyer shall be true and correct as of
the date when made and as of the Closing Date as though made at that time
(except for representations and warranties that speak as of a specific date),
and such Buyer shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required by this
Agreement to be performed, satisfied or complied with by such Buyer at or prior
to the Closing Date.


 


(iv)                              The
transactions contemplated by each Conversion and Amendment Agreement, dated as
of the date hereof, by and between the Company and each respective Buyer
(collectively, the “Conversion and Amendment
Agreements”), shall have been consummated.


 


(v)                                 The
Closing Bid Price (as defined in the Notes) of the Company Common Stock on the
date immediately prior to the Closing Date is not greater than Six Dollars
($6.00).


 


7.               CONDITIONS
TO EACH BUYER’S OBLIGATION TO PURCHASE.


 


(a)                                  Closing
Date.  The obligation of each Buyer
hereunder to purchase the Notes  and the related Warrants at the Closing is
subject to the satisfaction, at or before the Closing Date, of each of the
following conditions, provided that these conditions are for each Buyer’s sole
benefit and may be waived by such Buyer at any time in its sole discretion by
providing the Company with prior written notice thereof:


 


(i)                                     The
Company shall have executed and delivered to such Buyer (i) each of the
Transaction Documents and (ii) the Notes (in such principal amounts as such
Buyer shall have requested prior to the Closing)  and the related Warrants (in
such amounts as such Buyer shall have requested prior to the Closing) being
purchased by such Buyer at the Closing pursuant to this Agreement.


 


(ii)                                  Such
Buyer shall have received the opinion of Wilson Sonsini Goodrich & Rosati,
PC, the Company’s counsel, dated as of the Closing Date, in form, scope and
substance reasonably satisfactory to such Buyer and in substantially the form
of Exhibit H attached hereto.


 


(iii)                               The
Company shall have delivered to such Buyer a copy of the Irrevocable Transfer
Agent Instructions, in the form of Exhibit G attached hereto, which


 


25

















 


instructions shall have been delivered to and
acknowledged in writing by the Company’s transfer agent.


 


(iv)                              The
Company shall have delivered to such Buyer a certificate evidencing the
incorporation and good standing of the Company and Sparta Pharmaceuticals, Inc.
in each such corporation’s state of incorporation issued by the Secretary of
State of such state of incorporation as of a date within 10 days of the Closing
Date.


 


(v)                                 The
Company shall have delivered to such Buyer a certificate evidencing the
Company’s qualification as a foreign corporation and good standing issued by
the Secretary of State of California as of a date within 10 days of the Closing
Date.


 


(vi)                              The
Company shall have delivered to such Buyer a certified copy of the Certificate
of Incorporation as certified by the Secretary of State of the State of
Delaware within 10 days of the Closing Date.


 


(vii)                           The
Company shall have delivered to such Buyer a certificate, executed by the Chief
Executive Officer of the Company and dated as of the Closing Date, as to (i)
the resolutions consistent with Section 3(b) as adopted by the Company’s Board
of Directors (the “Resolutions”), (ii) the Certificate of
Incorporation and (iii) the Bylaws, each as in effect at the Closing, in the
form attached hereto as Exhibit I.


 


(viii)                        The
representations and warranties of the Company shall be true and correct as of
the date when made and as of the Closing Date as though made at that time
(except for representations and warranties that speak as of a specific date)
and the Company shall have performed, satisfied and complied in all respects
with the covenants, agreements and conditions required by the Transaction
Documents to be performed, satisfied or complied with by the Company at or
prior to the Closing Date.  Such Buyer
shall have received a certificate, executed by the Chief Executive Officer of
the Company, dated as of the Closing Date, to the foregoing in the form
attached hereto as Exhibit J.


 


(ix)                                The
Company shall have delivered to such Buyer a letter from the Company’s transfer
agent certifying the number of shares of Company Common Stock outstanding as of
a date within five days of the Closing Date.


 


(x)                                   The
Company Common Stock (I) shall be designated for quotation or listed on the
Principal Market and (II) shall not have been suspended by the SEC or the Principal
Market from trading on the Principal Market nor shall suspension by the SEC or
the Principal Market have been threatened either (A) in writing by the SEC or
the Principal Market or (B) by falling below the minimum listing maintenance
requirements of the Principal Market.


 


(xi)                                The
Company shall have obtained all governmental, regulatory or third party
consents and approvals, if any, necessary for the sale of the Notes and the
Warrants.


 


(xii)                             The
Company shall have delivered to such Buyer such other documents relating to the
transactions contemplated by this Agreement as such Buyer or its counsel may
reasonably request.


 


26

















 


(xiii)                          In
accordance with the terms of the Amended and Restated Pledge Agreement and the
Amended and Restated Securities Account Control Agreement, the Custodian shall
have possession of the certificate(s) representing the AVII Shares, along with
duly executed blank stock powers.


 


(xiv)                         The
Company shall have delivered to such Buyer a true, correct and complete copy of
each prospectus pursuant to the AVII Registration Statements in accordance with
Section 4(r).


 


(xv)                            The
transactions contemplated by all of the Conversion and Amendment Agreements
shall have been consummated.


 


8.               TERMINATION.  In the event that the Closing shall not have
occurred with respect to a Buyer on or before five (5) Business Days from the
date hereof due to the Company’s or such Buyer’s failure to satisfy the
conditions set forth in Sections 6 and 7 above (and the nonbreaching party’s
failure to waive such unsatisfied condition(s)), the nonbreaching party shall
have the option to terminate this Agreement with respect to such breaching
party at the close of business on such date without liability of any party to
any other party; provided, however, this if this Agreement is terminated
pursuant to this Section 8, the Company shall remain obligated to reimburse the
non-breaching Buyers for the expenses described in Section 4(g) above.


 


9.               MISCELLANEOUS.


 


(a)                                  Governing
Law; Jurisdiction; Jury Trial.  All
questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New
York, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of New York or any other jurisdictions) that
would cause the application of the laws of any jurisdictions other than the
State of New York.  Each party hereby
irrevocably submits to the non-exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the
adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein, and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the
venue of such suit, action or proceeding is improper.  Each party hereby irrevocably waives personal service of process
and consents to process being served in any such suit, action or proceeding by
mailing a copy thereof to such party at the address for such notices to it
under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any
right to serve process in any manner permitted by law.  EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY
TRANSACTION CONTEMPLATED HEREBY.


 


(b)                                 Counterparts.  This Agreement may be executed in two or
more identical counterparts, all of which shall be considered one and the same
agreement and shall become


 


27

















 


effective when counterparts have been signed
by each party and delivered to the other party; provided that a facsimile
signature shall be considered due execution and shall be binding upon the
signatory thereto with the same force and effect as if the signature were an
original, not a facsimile signature.


 


(c)                                  Headings.  The headings of this Agreement are for
convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.


 


(d)                                 Severability.  If any provision of this Agreement shall be
invalid or unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or
enforceability of any provision of this Agreement in any other jurisdiction.


 


(e)                                  Entire
Agreement; Amendments.  This
Agreement supersedes all other prior oral or written agreements between the
Buyers, the Company, their affiliates and Persons acting on their behalf with
respect to the matters discussed herein, and this Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect
to the matters covered herein and therein and, except as specifically set forth
herein or therein, neither the Company nor any Buyer makes any representation,
warranty, covenant or undertaking with respect to such matters.  No provision of this Agreement may be
amended other than by an instrument in writing signed by the Company and the
holders of Notes representing at least a majority of the aggregate principal
amount of the Notes, or, if prior to the Closing Date, the Company and the
Buyers listed on the Schedule of Buyers as being obligated to purchase at least
a majority of the aggregate principal amount of the Notes, and any amendment to
this Agreement made in conformity with the provisions of this Section 9(e)
shall be binding on all Buyers and holders of Notes, as applicable.  No provision hereof may be waived other than
by an instrument in writing signed by the party against whom enforcement is
sought.  No such amendment shall be
effective to the extent that it applies to less than all of the holders of the
Notes then outstanding.  No
consideration shall be offered or paid to any Person to amend or consent to a
waiver or modification of any provision of any of the Transaction Documents
unless the same consideration also is offered to all of the parties to the
Transaction Documents, holders of Notes or holders of the Warrants, as the case
may be.  The Company has not, directly
or indirectly, made any agreements with any Buyers relating to the terms or
conditions of the transactions contemplated by the Transaction Documents except
as set forth in the Transaction Documents.


 


(f)                                    Notices.  Any notices, consents, waivers or other
communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered:  (i) upon receipt, when delivered personally;
(ii) upon receipt, when sent by facsimile (provided confirmation of transmission
is mechanically or electronically generated and kept on file by the sending
party); or (iii) one Business Day after deposit with an overnight courier
service, in each case properly addressed to the party to receive the same.  The addresses and facsimile numbers for such
communications shall be:


 


If to the Company:


 


SuperGen, Inc.

4140 Dublin Boulevard


 


28

















 


Suite 200

Dublin, California 94568

Telephone:                                    (925)
560-0100

Facsimile:                                            (925)
560-0101

Attention:                                         Chief
Executive Officer


 


with a copy to:


 


Wilson Sonsini Goodrich & Rosati, PC

650 Page Mill Road

Palo Alto, California 93404

Telephone:                                    (650)
493-9300

Facsimile:                                            (650)
493-6811

Attention:                                         John
V. Roos, Esq.


 


If to the Transfer Agent:


 


Mellon Investor Services LLC

235 Montgomery Street

23rd Floor

San Francisco, California  94104

Telephone:                                    (415)
743-1426

Facsimile:                                            (415)
989-5241

Attention:                                         David
Altschul


 


If to a Buyer, to its address
and facsimile number set forth on the Schedule of Buyers, with copies to such
Buyer’s representatives as set forth on the Schedule of Buyers, or to such
other address and/or facsimile number and/or to the attention of such other
Person as the recipient party has specified by written notice given to each
other party five (5) days prior to the effectiveness of such change.  Written confirmation of receipt (A) given by
the recipient of such notice, consent, waiver or other communication, (B)
mechanically or electronically generated by the sender’s facsimile machine
containing the time, date, recipient facsimile number and an image of the first
page of such transmission or (C) provided by an overnight courier service shall
be rebuttable evidence of personal service, receipt by facsimile or receipt
from an overnight courier service in accordance with clause (i), (ii) or (iii)
above, respectively.


 


(g)                                 Successors
and Assigns.  This Agreement shall
be binding upon and inure to the benefit of the parties and their respective
successors and assigns, including any purchasers of the Notes or the
Warrants.  The Company shall not assign
this Agreement or any rights or obligations hereunder without the prior written
consent of the holders of Notes representing at least a majority of the
aggregate principal amount of the Notes then outstanding, including by merger
or consolidation, except pursuant to a Change of Control (as defined in Section
5(a) of the Notes) with respect to which the Company is in compliance with
Section 5 of the Notes and Section 4(b) of the Warrants.  A Buyer may assign some or all of its rights
hereunder without the consent of the Company, in which event such assignee
shall be deemed to be a Buyer hereunder with respect to such assigned rights.


 


29

















 


(h)                                 No
Third Party Beneficiaries.  This
Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns, and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person.


 


(i)                                     Survival.  Unless this Agreement is terminated under
Section 8, the representations and warranties of the Company and the Buyers
contained in Sections 2 and 3 and the agreements and covenants set forth in
Sections 4, 5 and 9 shall survive the Closing. 
Each Buyer shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.


 


(j)                                     Further
Assurances.  Each party shall do and
perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates,
instruments and documents, as any other party may reasonably request in order
to carry out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby.


 


(k)                                  Indemnification.  In consideration of each Buyer’s execution and
delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of the Company’s other obligations under the Transaction
Documents, the Company shall defend, protect, indemnify and hold harmless each
Buyer and each other holder of the Securities and all of their stockholders,
partners, members, officers, directors, employees and direct or indirect
investors and any of the foregoing Persons’ agents or other representatives
(including, without limitation, those retained in connection with the
transactions contemplated by this Agreement) (collectively, the “Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses,
costs, penalties, fees, liabilities and damages, and expenses in connection
therewith (irrespective of whether any such Indemnitee is a party to the action
for which indemnification hereunder is sought), and including reasonable
attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any
Indemnitee as a result of, or arising out of, or relating to (a) any
misrepresentation or breach of any representation or warranty made by the
Company in the Transaction Documents or any other certificate, instrument or
document contemplated hereby or thereby, (b) any breach of any covenant,
agreement or obligation of the Company contained in the Transaction Documents
or any other certificate, instrument or document contemplated hereby or thereby
or (c) any cause of action, suit or claim brought or made against such Indemnitee
by a third party (including for these purposes a derivative action brought on
behalf of the Company) and arising out of or resulting from (i) the execution,
delivery, performance or enforcement of the Transaction Documents or any other
certificate, instrument or document contemplated hereby or thereby, (ii) any
disclosure made by such Buyer pursuant to Section 4(i), or (iii) the status of
such Buyer or holder of the Securities as an investor in the Company pursuant
to the transactions contemplated by the Transaction Documents.  To the extent that the foregoing undertaking
by the Company may be unenforceable for any reason, the Company shall make the
maximum contribution to the payment and satisfaction of each of the Indemnified
Liabilities which is permissible under applicable law.  Except as otherwise set forth herein, the
mechanics and procedures with respect to the rights and obligations under this
Section 9(k) shall be the same as those set forth in Section 6 of the
Registration Rights Agreement.


 


30

















 


(l)                                     No
Strict Construction.  The language
used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be
applied against any party.


 


(m)                               Remedies.  Each Buyer and each holder of the Securities
shall have all rights and remedies set forth in the Transaction Documents and
all rights and remedies which such holders have been granted at any time under
any other agreement or contract and all of the rights which such holders have
under any law.  Any Person having any
rights under any provision of this Agreement shall be entitled to enforce such
rights specifically (without posting a bond or other security), to recover
damages by reason of any breach of any provision of this Agreement and to
exercise all other rights granted by law. 
Furthermore, the Company recognizes that in the event that it fails to
perform, observe, or discharge any or all of its obligations under this Agreement,
any remedy at law may prove to be inadequate relief to the Buyers.  The Company therefore agrees that the Buyers
shall be entitled to seek temporary and permanent injunctive relief in any such
case without the necessity of proving actual damages and without posting a bond
or other security.


 


(n)                                 Payment
Set Aside.  To the extent that the
Company makes a payment or payments to the Buyers hereunder or pursuant to any
of the other Transaction Documents or the Buyers enforce or exercise their
rights hereunder or thereunder, and such payment or payments or the proceeds of
such enforcement or exercise or any part thereof are subsequently invalidated,
declared to be fraudulent or preferential, set aside, recovered from, disgorged
by or are required to be refunded, repaid or otherwise restored to the Company,
a trustee, receiver or any other Person under any law (including, without
limitation, any bankruptcy law, state or federal law, common law or equitable
cause of action), then to the extent of any such restoration the obligation or
part thereof originally intended to be satisfied shall be revived and continued
in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred.


 


(o)                                 Independent
Nature of Buyers’ Obligations and Rights. 
The obligations of each Buyer under any Transaction Document are several
and not joint with the obligations of any other Buyer, and no Buyer shall be
responsible in any way for the performance of the obligations of any other
Buyer under any Transaction Document. 
Nothing contained herein or in any other Transaction Document, and no
action taken by any Buyer pursuant hereto or thereto, shall be deemed to
constitute the Buyers as a partnership, an association, a joint venture or any
other kind of entity, or create a presumption that the Buyers are in any way
acting in concert or as a group with respect to such obligations or the
transactions contemplated by the Transaction Documents.  Each Buyer confirms that it has
independently participated in the negotiation of the transaction contemplated
hereby with the advice of its own counsel and advisors.  Each Buyer shall be entitled to
independently protect and enforce its rights, including, without limitations,
the rights arising out of this Agreement or out of any other Transaction
Documents, and it shall not be necessary for any other Buyer to be joined as an
additional party in any proceeding for such purpose.


 


[Signature Page
Follows]


 


31

















 


IN WITNESS WHEREOF,
each Buyer and the Company have caused this Securities Purchase Agreement to be
duly executed as of the date first written above.


 


	
  COMPANY:

  	
  BUYERS:

  
	
   

  	
   

  
	
  SUPERGEN, INC.

  	
  SMITHFIELD
  FIDUCIARY LLC

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Joseph Rubinfeld

  	
   

  	
  Name:

  	
  Adam J. Chill

  
	
   

  	
  Title:

  	
  President/Chief Executive Officer

  	
   

  	
  Title:

  	
  Authorized Signatory

  
	
   

  	
   

  
	
   

  	
  OMICRON MASTER
  TRUST

  
	
   

  	
   

  
	
   

  	
  By:

  	
  Omicron Capital L.P., as investment advisor

  
	
   

  	
  By:

  	
  Omicron Capital Inc., its general partner

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Olivier Morali

  
	
   

  	
   

  	
  Title:

  	
  President

  
	
   

  	
   

  
	
   

  	
  MAINFIELD ENTERPRISES INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Avi Vigder

  
	
   

  	
   

  	
  Title:

  	
  Director

  
	
   

  	
   

  
	
   

  	
  CRANSHIRE CAPITAL
  L.P.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Mitchell P. Kopin

  
	
   

  	
   

  	
  Title:

  	
  President-Downsview Capital, Inc.,

  The General Partner

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  OTAPE LLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Richard Cayne

  
	
   

  	
   

  	
  Title:

  	
  General Counsel

  
									



 


32

















 


SCHEDULE OF BUYERS


 


	
  (1)

  	
   

  	
  (2)

  	
   

  	
  (3)

  	
   

  	
  (4)

  	
   

  	
  (5)

  
	
  Buyer

  	
   

  	
  Address
  and Facsimile Number

  	
   

  	
  Aggregate
  Principal

  Amount of

  Notes

  	
   

  	
  Aggregate

  Number of

  Warrants

  	
   

  	
  Legal
  Representative’s

  Address and Facsimile Number

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Smithfield
  Fiduciary LLC

  	
   

  	
  c/o Highbridge Capital

  Management, LLC

  9 West 57th Street, 27th Floor

  New York, New York  10019

  Attention:  Ari J. Storch

  Adam J. Chill

  Facsimile:  (212) 751-0755

  Telephone: (212) 287-4720

  Residence:  Cayman Islands

  	
   

  	
  $

  	
  10,750,000

  	
   

  	
  1,332,601

  	
   

  	
  Schulte Roth & Zabel LLP

  919 Third Avenue

  New York, New York  10022

  Attention:  Eleazer Klein, Esq.

  Facsimile: (212) 593-5955

  Telephone:  (212) 756-2376

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Omicron Master Trust

  	
   

  	
  c/o Omicron Capital L.P.

  810 Seventh Avenue

  39th Floor

  New York, New York 10019
Attention:  Olivier Morali

  Facsimile:  (212) 803-5269

  Telephone:  (212) 803-5262

  Residence: Bermuda

  	
   

  	
  $

  	
  4,250,000

  	
   

  	
  526,841

  	
   

  	
  The Law Offices of Brian Pusch

  29 West 57th  Street

  New York, New York 10019

  Attention:  Brian Pusch, Esq.

  Facsimile:  (212) 980-7055

  Telephone:  (212) 980-0408

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Mainfield Enterprises Inc.

  	
   

  	
  c/o Cavallo Capital Corp.

  660 Madison Avenue, 18th Floor,

  New York, New York  10021

  Attention:  Mor Sagi

  Facsimile:  (212) 651-9010

  Telephone:  (212) 651-9005

  Residence: British Virgin Islands

  	
   

  	
  $

  	
  4,000,000

  	
   

  	
  495,851

  	
   

  	
  Bryan Cave LLP

  1290 Ave of the Americas

  New York, New York 10104

  Attention:  Ken Henderson, Esq.

  Facsimile:  (212) 541-1357

  Telephone:  (212) 541-2275

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cranshire Capital L.P.

  	
   

  	
  c/o Downsview Capital, Inc.

  The General Partner

  666 Dundee Road, Suite 1901

  Northbrook, Ilinois  60062

  Attention:  Mitchell D. Kopin

  Facsimile:  (847)
  562-9031

  Telephone:  (847) 562-9030

  Residence: Illinois

  	
   

  	
  $

  	
  1,250,000

  	
   

  	
  154,954

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  OTAPE LLC

  	
   

  	
  c/o OTA LLC

  1 Manhattanville Rd.

  Purchase, New York  10577

  Attention:  Paul Masters

  Facsimile:  (914) 694-6335

  Telephone:  (914) 694-5857

  Residence: Delaware

  	
   

  	
  $

  	
  1,000,000

  	
   

  	
  123,964

  	
   

  	
  Piper Rudnick LLP

  1251 Avenue of the Americas

  New York, New York  10020

  Attention:  Theodore Altman,

  Esq. Facsimile:  (212) 835-6001

  Telephone:  (212) 835-6000

  



 


33

















 


EXHIBITS


 


	
  Exhibit A

  	
  Form of
  Notes

  
	
  Exhibit B

  	
  Form of
  Warrants

  
	
  Exhibit C

  	
  Form of
  Amended and Restated Pledge Agreement

  
	
  Exhibit D

  	
  Form of
  Amended and Restated Securities Account Control Agreement

  
	
  Exhibit E

  	
  Form of Cash
  Collateral Account Control Agreement

  
	
  Exhibit F

  	
  Form of
  Registration Rights Agreement

  
	
  Exhibit G

  	
  Form of
  Irrevocable Transfer Agent Instructions

  
	
  Exhibit H

  	
  Form of
  Company Counsel Opinion

  
	
  Exhibit I

  	
  Form of
  Chief Executive Officer’s Certificate

  
	
  Exhibit J

  	
  Form of
  Officer’s Certificate

  



 


SCHEDULES


 


	
  Schedule
  3(a)

  	
  Subsidiaries

  
	
  Schedule
  3(d)

  	
  No Conflict

  
	
  Schedule
  3(m)

  	
  Undisclosed
  Liabilities

  
	
  Schedule
  3(p)

  	
  Transactions
  with Affiliates

  
	
  Schedule
  3(q)

  	
  Capitalization

  
	
  Schedule
  3(r)

  	
  Indebtedness
  and Other Contracts

  
	
  Schedule
  3(s)

  	
  Litigation

  
	
  Schedule
  3(v)

  	
  Title

  



 


34